NOV 14, 2018 8:02 PM PST

Reversing T Cell dysfunction in Cancer: Getting the Body to Fight its own Battles

Using the power of the immune system to eliminate cancerous cells has long the been the goal of immuno-oncology. Immune cells naturally recognize, destroy, and remember the abnormal cells within our bodies while also overlooking healthy cells. This process is called self-tolerance, and when working well, allows the body to rid itself of abnormalities without collateral damage. The challenge with cancer is that tumors can co-opt a variety of self-tolerance mechanisms to evade the destructive potential of the immune system.

Cytotoxic T cells (red) attacking an oral squamous cancer cell (white) by Rita Elena Serda

Self tolerance prevents the immune system from becoming overactive and protects against autoimmunity. Autoreactive immune cells are either destroyed or left inactive. For example, circulating T cells are prevented from excessive proliferation and cytotoxicity by signaling molecules expressed on tissue and regulatory T cells with suppressive functions called Tregs. Tumors take advantage of this self tolerance in order to grow unchecked. A comprehensive approach to reversing this dysfunction by (1) activating cancer-specific cytotoxic T cells, (2) releasing T reg suppression, and (3) producing tumor-specific memory T cells has been termed the immune checkpoint blockade.

Current attempts to achieve the immune checkpoint blockade have focused on targeting signaling molecules involved in maintaining self tolerance. Two such proteins are PD-1 and GITR, and both are frequently exploited by tumors. PD-1 is a protein that acts as a “brake” for the immune system. It is expressed on immune cells including T cells and T regs. Its ligand is expressed on both healthy tissue and tumors. PD-1 signaling inhibits the activity of cytotoxic T cells while promoting the expansion of Tregs.

GITR is a cell surface receptor that acts as an “accelerator” for the immune system. Like PD-1, GITR is found on activated T cells and Tregs, but it has the opposite function. GITR signaling promotes cytotoxic T cell expansion and inhibits Treg activity.

Initially, scientists attempted to activate anti-tumor immunity by either inhibiting PD-1 signaling (cutting the “brakes”) or activating GITR signaling (revving the “accelerator”). Neither indvidual approach was able to achieve immune checkpoint blockade. However, a combinatorial method using an antibody to block PD-1 signaling (anti-PD-1) while simultaneously activating GITR signaling by antibody (anti-GITR) has shown promise.

“In preclinical studies in which monotherapy with anti-GITR or anti–PD-1 Ab has limited efficacy… combination therapy was able to achieve long-term survival in mouse models of ovarian and breast cancer”

To study this anti-tumor treatment, Bei Wang and others at Regeneron Pharmaceuticals used a murine colon adenocarcinoma model to analyze populations of intratumoral cytotoxic CD8+ T cells and Tregs following treatment with anti-PD-1 and/or anti-GITR antibodies. Monotherapy with either anti-PD-1 or anti-GITR were not capable of controlling tumor growth as neither could overcome the immune checkpoint. However, the combination therapy resulted in the rejection of the tumors along with in an increased ratio of T cells to Tregs. Further studies showed that tumor rejection was CD8+ T cell dependent, cancer specific, and that the CD8+ T cells contained memory cell precursors suggesting anti-tumor memory.

The higher numbers of functional CD8+ T cells compared to Tregs along with the rejection of the tumors and presence of memory cell precursors after the combination treatment suggests that the immune checkpoint blockade was successful. Excitingly, this therapy does not appear to be cancer type specific as anti-PD-1 + anti-GITR treatment also resulted in rejection of a mouse model of kidney carcinoma.


It will be interesting to see whether this combination treatment, with or without cancer vaccination or chemotherapy, has the same dramatic results in humans.

Sources: European Journal of CancerScience ImmunologyJohns Hopkins Medicine;

About the Author
  • Aleishia is a freelance medical/science writer that specializes in research-oriented content. Contact her for work.
You May Also Like
FEB 25, 2021
Immunology
Asthma Inhalers Slash Risk of COVID Hospitalization by 90 Percent
FEB 25, 2021
Asthma Inhalers Slash Risk of COVID Hospitalization by 90 Percent
For mild cases of COVID, doctors recommend the usual regimen for getting through a cold or flu: Staying hydrated and res ...
MAR 11, 2021
Immunology
Bye-Bye Burning: A New UTI Vaccine
MAR 11, 2021
Bye-Bye Burning: A New UTI Vaccine
Researchers have developed a vaccine that “trains” the bladder to fight back against the bacteria that cause ...
MAR 22, 2021
Immunology
Gene Mutation Keeps Tumors "Cold"
MAR 22, 2021
Gene Mutation Keeps Tumors "Cold"
Immunologists have identified a mechanism through which an oncogene mutation shields pancreatic tumors from immune cells ...
APR 11, 2021
Genetics & Genomics
Trial Shows Personalized Cancer Vaccines are Safe
APR 11, 2021
Trial Shows Personalized Cancer Vaccines are Safe
Vaccines are mostly known as tools to prevent illness. But cancer vaccines are a bit different, and aim to treat existin ...
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
MAY 24, 2021
Immunology
How Grief Can Affect the Immune System
MAY 24, 2021
How Grief Can Affect the Immune System
A new study by researchers at Rice University has shown that sleep loss often following the death of a spouse can have l ...
Loading Comments...